Phase III trial of Keytruda meets endpoint for treating ovarian cancer: MSD

MSD’s Phase III KEYNOTE-B96 trial showed that Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), with or without bevacizumab, improved progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer. The trial included patients with PD-L1-positive tumors and all-comers. A secondary endpoint of overall survival (OS) was met in PD-L1-positive patients (CPS ≥1). Interim analysis showed PFS benefits regardless of PD-L1 status.

Keytruda, given as 400 mg IV every six weeks for two years, was tested against placebo plus chemotherapy in about 643 patients. The safety profile was consistent with previous studies, with no new concerns.

Keytruda is an anti-PD-1 antibody that boosts immune response by blocking PD-1 interaction with its ligands, activating T cells to fight tumors. MSD noted this is the first immune checkpoint inhibitor regimen to show an OS benefit in ovarian cancer. Recent positive results were also reported for subcutaneous Keytruda in lung cancer.

16-05-2025